A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An
about
Cytotoxic and targeted therapy for hereditary cancersNew treatment option for ovarian cancer: PARP inhibitorsTrial watch - inhibiting PARP enzymes for anticancer therapyRole of Biomarkers in the Development of PARP InhibitorsTargeting dormant micrometastases: rationale, evidence to date and clinical implicationsPARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future PerspectivesOvarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengePARP inhibitors in the management of breast cancer: current data and future prospectsProfile of veliparib and its potential in the treatment of solid tumorsPARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesMolecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentPARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsChemoresistance and targeted therapies in ovarian and endometrial cancersUpdate on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentConcepts and targets in triple-negative breast cancer: recent results and clinical implicationsPhase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast CancerPARP inhibitors in ovarian cancer: evidence, experience and clinical potential"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsDrugging the Cancers Addicted to DNA Repair.Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerRandomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian CancerTreatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report.Identification of several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assayRational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't knowRandomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancerEvaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.An overview of early investigational therapies for chemoresistant ovarian cancer.An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.BRCA mutation in ovarian cancer: testing, implications and treatment considerations.Veliparib for the treatment of ovarian cancer.Current and emerging treatment options in the management of advanced ovarian cancer.New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.Targeted agents and combinations in ovarian cancer: where are we now?What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?PARP inhibitors as antitumor agents: a patent update (2013-2015).A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
P2860
Q26739366-28D2564D-2177-47B6-9E34-A411909483E8Q26745614-C34E85DE-B5AF-47E6-9DDB-A373FB8E9B84Q26745673-49F4C819-2108-4618-B34F-2EB8B347DEC0Q26753159-1E919511-B18E-4088-825F-49793919A01AQ26765205-9B2F1636-4F4B-43E6-BB21-B959D0893086Q26768661-5F61771E-3A76-46A7-B393-8867716BBB9DQ26777846-22D7BA0F-F97F-46C2-B840-CCD661250621Q26798352-6F52364C-2641-43D4-865C-00B425C02617Q26801272-066C0B1E-E818-430D-8271-08F9D37E94F0Q27027503-C8DA6398-5C91-4AFC-9E2B-DD7BA2BCCD2AQ28066904-CC30BA02-F4AC-427A-8A74-C16D86FBE8BFQ28071345-BC2E9BBD-F525-4606-984D-06B2A6FEDE83Q28073246-A9DB20EA-3264-4716-90F1-CEE488198386Q28075761-606069C0-57C7-4BFE-BED5-CEECFB89DD55Q28078992-4D6C5339-C9E3-404E-8D60-749854F1D62DQ33429434-08EEDE9D-DC73-429B-ABC7-D0E947CA1249Q33605912-AF327836-9EA1-48E7-B6E4-C37DA28DA80EQ33618910-DA6878D7-FDFC-4F16-9331-5895878889D3Q33702497-0E4C2F73-C1DC-436F-A2DB-B93BEEF5438AQ33704050-43212221-B443-4A92-A7BD-0D3CDA6929AAQ35251489-A0A214D1-24AE-4656-89D7-3085600BE1EEQ36094171-0E5C6162-5F06-4887-B1C9-83C4F0121D02Q36275846-6933583B-4172-45A6-83BF-3A673EFFAB50Q36731185-7B31FB3A-D6A7-416C-BF99-FCEA9F124C7FQ36880037-A821BAA3-FA17-4900-9FAD-DE09151D6880Q37158437-055339D5-CE83-418B-8DDA-CB7BC43C5606Q37228176-51889C02-7014-4DEB-9294-29A535069D51Q37605747-3AE041E0-D510-44EF-ADA7-043DAA8CAFA6Q37607283-05ADB358-93B9-4C4F-982E-CAEC3280D247Q37661436-D84230E8-39F1-4266-B399-490CCA46C7F9Q38553247-7AC32AEB-BDDC-4AE1-A001-867D620B0E0BQ38631373-2942C707-C0AA-49C2-A91A-D13F429302F0Q38644661-6851A00B-E1B8-4FE8-90B8-1DF6CE3BEC2AQ38710466-2B4DAE6D-1EB3-44B9-91D3-958CF6320690Q38751236-0C75D6B3-DD26-4BD3-A869-5D606967DA12Q38756892-B503C704-4057-4D6D-AA1D-059FAF87020FQ38760610-32EEA5DF-C222-4133-984A-BD29A148E855Q38777616-2D6B26D7-282B-406C-AB45-C94B8C32499FQ38795712-1B8ED5FC-4D33-4EA6-8AF5-553F7A010F83Q38811820-8B2859B8-DBA4-4091-A959-25087BC75414
P2860
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A phase II evaluation of the p ...... e BRCA1 or BRCA2 mutation - An
@ast
A phase II evaluation of the p ...... e BRCA1 or BRCA2 mutation - An
@en
A phase II evaluation of the p ...... e BRCA1 or BRCA2 mutation - An
@nl
type
label
A phase II evaluation of the p ...... e BRCA1 or BRCA2 mutation - An
@ast
A phase II evaluation of the p ...... e BRCA1 or BRCA2 mutation - An
@en
A phase II evaluation of the p ...... e BRCA1 or BRCA2 mutation - An
@nl
prefLabel
A phase II evaluation of the p ...... e BRCA1 or BRCA2 mutation - An
@ast
A phase II evaluation of the p ...... e BRCA1 or BRCA2 mutation - An
@en
A phase II evaluation of the p ...... e BRCA1 or BRCA2 mutation - An
@nl
P2093
P2860
P3181
P1433
P1476
A phase II evaluation of the p ...... e BRCA1 or BRCA2 mutation - An
@en
P2093
Alice Chen
Carol Aghajanian
Elizabeth M Swisher
Heidi J Gray
John K Chan
Katherine Bell-McGuinn
Krishnansu S Tewari
Michael W Sill
Robert L Coleman
Steven C Rubin
P2860
P304
P3181
P356
10.1016/J.YGYNO.2015.03.042
P407
P577
2015-03-24T00:00:00Z